Novel benzofuran-2-carboxamide ligands, which are selective for sigma receptors, have been synthesized via a microwave-assisted Perkin rearrangement reaction and a modified Finkelstein halogen-exchange used to facilitate N-alkylation. The ligands synthesized are the 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamides (KSCM-1, KSCM-5 and KSCM-11). The benzofuran-2-carboxamide structure was N-arylated and N-alkylated to include both N-phenyl and N-(3-(piperidin-1-yl) propyl substituents respectively. These new carboxamides exhibit high affinity at the sigma-1 receptor with K i values ranging from 7.8 -34nM. Ligand KSCM-1 with two methoxy substituents at C-5 and C-6 of the benzofuran ring, and K i = 27.5nM at sigma-1 was found to be more selective for sigma-1 over sigma-2.
INTRODUCTION
In the mid-70s sigma receptors were mistakenly characterized as a new subtype of opioid receptors. 1 However, cloning of the guinea pig sigma-1 binding site in 1996 revealed this protein to be unique sharing no homology with any other mammalian protein including all types of molecular chaperones. 2 Sigma receptors are classified into two subtypes, sigma-1 and sigma-2. To date, the sigma-2 receptor has not been cloned. Sigma-1 receptors are endoplasmic reticular (ER) proteins consisting of 223-amino acids with a molecular mass of 24-kDa, and two-transmembrane-spanning regions. 3, 4 Sigma-1 receptors are widely distributed throughout the body, centrally and peripherally, primarily functioning in a modulatory role on dopamine, acetylcholine, NMDA and opioid receptors. 5 They are known to translocate during signal transduction and have been linked to the modulation or production of various intracellular secondary messengers. 3, 6 Sigma-2 receptors are understood to be slightly smaller in size than the sigma-1 receptor. Pharmacological evaluations reveal that sigma-2 receptors may be lipid raft proteins that affect calcium signaling via sphingolipid products and unlike sigma-1 receptors, sigma-2 receptors do not translocate. 7 Both sigma receptors are highly expressed on tumor cell lines from human and rat cancer tissues. The overexpression of sigma-2 receptors in human and murine tumors suggests that these receptors may be a biomarker of tumor cell proliferation. 7 Various drugs, including antipsychotics (morphine analogs), neuroleptics (haloperidol) and neuroactive steroids (progesterone, DHEA), bind to sigma-1 receptors. 8 Ligands that bind to and modulate the sigma-1 receptor have been proposed to exhibit effects in several therapeutic areas such as neurodegenerative disorders, pain, depression, schizophrenia, amnesia, Alzheimer's disease, Parkinson's disease and stroke. 8 Sigma-1 receptors have also been documented as a target for cocaine and associated with the toxic and stimulant actions of cocaine. 7 In general sigma-1 antagonists may have potential use in the treatment of addiction.
The binding site of sigma-1 receptors is reported to consist of an amine binding site flanked on either side by hydrophobic binding pockets that display bulk tolerance and as such, typical pharmacophoric features of sigma-1 receptors include an alkylamine moiety within the general molecular structure. 9 Hence, a common pharmacophoric feature of sigma-1 ligands is an N-alkyl, N,N-dialkyl or N-arylalkyl amine moiety 10 which poses a challenge in the synthesis of these ligands. Interestingly, progesterone which lacks a basic nitrogen, is considered one of the putative endogenous ligands for the sigma-1 receptor. 11 N,N-Dimethyltryptamine (DMT)
has been identified as a potential endogenous sigma-1 receptor ligand, but, the role of DMT as a sigma-1 receptor modulator is unclear due to low physiological concentrations in brain tissues. 12 Our synthesized ligands have a benzofuran-2-carboxamide structural moiety which has been N-arylated and N-alkylated to include both N-phenyl and N-(3-(piperidin-1-yl)propyl substituents respectively, as summarized structurally in Figure 1 . These new carboxamide ligands structurally consist of a basic alkylamine moiety the N- (3-(piperidin-1-yl) propyl with a protonatable nitrogen and an aromatic phenyl ring and benzofuran moiety as two hydrophobic residues ( Figure 1 ). Additionally, we introduced structural variations at the benzofuran moiety in the form of methyl ether substituents (R 1 and R 2 , Figure 1 ) to investigate the effect these substituents have on receptor binding affinity. 
RESULTS AND DISCUSSION
Chemistry. Our microwave-assisted expedited synthetic pathway is straightforward, involving the preparation of 3-methylbenzofuran-2-carboxylic acids (1a and 1b) in quantitative yields via a Perkin rearrangement reaction of mono-and di-methoxy-3-bromocoumarins as previously described. 13 Mono-and di-hydroxycoumarins were methylated and subsequently brominated at position-3 via a microwave-assisted regioselective bromination with Nbromosuccinimide (NBS) to yield mono-and di-methoxy-3-bromocoumarins in 85-89% yields.
13
Scheme 1 Reagents: a) DCC, DMAP, aniline, CH 2 Cl 2 ; b) NaH, 1-(3-chloropropyl)piperidine.HCl, K 2 CO 3 , KI, TBAB, CH 2 Cl 2 .
3-Bromocoumarins traditionally undergo base-catalyzed Perkin rearrangement, which requires 3 hours reflux quantitatively yielding benzofuran-2-carboxylic acids.
14 However under microwave reaction conditions these reactions were completed in 5 minutes. 13 Mono-and dimethoxy-3-methyl-N-phenylbenzofuran-2-carboxamides (2a and 2b) were produced by (Tables 1 and 2 ) were forwarded for additional screening (secondary binding assays) to determine K i values at the respective GPCR binding sites using radioligand binding assays. It was determined that compounds KSCM-1, KSCM-5 and KSCM-11 have the desired selectivity for sigma receptors (sigma-1 and sigma-2) over non-sigma receptors.
INSERT Table 1 INSERT Table 2 Secondary binding assays of these compounds showed greater affinity at sigma receptors over non-sigma receptors such as 5-HT2A, 5-HT2B, 5HT3, Alpha2A, Alpha2C, D3, and M4 (Tables 3 and 4) . Consistent with documented sigma-1 receptor ligands, the molecular structures of KSCM-1, KSCM-5 and KSCM-11 include a basic alkyl amine group, flanked by two hydrophobic residues (an aromatic phenyl and benzofuran ring). Table 3 INSERT Table 4 Based upon the sigma-1 receptor selective ligand pharmacophore profile [10] , a sigma-1 selective ligand usually possesses a primary and secondary hydrophobic site separated by an amine. The sigma-1 receptor site displays some bulk tolerance and so this prompted us to explore introducing a benzofuran moiety to produce the general molecular structure summarized in Figure 1 . All three compounds have an N-arylated benzofuran-2-carboxamide scaffold which was then N-alkylated yielding N- (3-(piperidin-1-yl) propyl introducing a basic protonatable nitrogen as well as a three-carbon alkyl linker as summarized structurally in Figure 1 . Additionally, the benzofuran molecular structure was varied by substitutions at C-5
INSERT
and C-6 with methyl ether (R 1 and R 2 , Figure 1 ) to explore the impact that introduction of additional hydrogen bond acceptor (HBA) centers would have on receptor binding affinity and selectivity. We observed that the inclusion of methoxy substituents at both C-5 and C-6 of the benzofuran moiety resulted in both high affinity and selectivity at the sigma-1 receptor over the sigma-2 receptor as observed for KSCM-1 with K i = 27.5nM at sigma-1 and 528nM
at sigma-2 (19-fold selectivity for sigma-1 over sigma-2, Table 3 ). KSCM-1 showed no significant affinity at non-sigma receptors selected for secondary binding assay, K i determination (Table 4) , with K i values ranging from 945nM at Alpha2A to 7,612nM at 5-HT3. The exclusion of a methoxy substituent at C-5 of the benzofuran moiety to produce KSCM-11 resulted in a slightly decreased affinity at sigma-1 (K i = 34nM, Table 3 ), however, a significant increase in affinity at sigma-2 (K i = 41nM, Table 3 ) in comparison to KSCM-1.
The mono-methoxy compound KSCM-11 has similar affinity at both sigma receptor binding sites and thus no significant selectivity of sigma-1 over sigma-2 was observed (K i =34nM at sigma-1 and 41nM at sigma-2, Table 3 ). KSCM-11 showed no significant affinity at nonsigma receptors selected for secondary binding assay, K i determination (Table 4) , with K i values ranging from 204nM at 5-HT2B to >10,000nM at M4. The exclusion of both methoxy substituents at C-5 and C-6 of the benzofuran moiety to produce KSCM-5 resulted in a significantly increased affinity at both sigma-1 (Ki = 7.8nM, Table 3 ) and sigma-2 (Ki = 16nM, Table 3 ) in comparison to KSCM-1 and KSCM-11. However, selectivity of KSCM-5 for sigma-1 over the sigma-2 was only 2-fold. KSCM-5 showed no significant affinity at nonsigma receptors selected for secondary binding assay, K i determination (Table 4) All new compounds were purified on a Biotage Isolera-4 flash purification system using the indicated SNAP cartridges and solvents as eluents.
In Vitro Characterization, Primary and Secondary Binding Experiments
Radioligand binding assays using cloned G-protein coupled receptors (GPCRs), ion channels, 
Ligand Synthesis

6-Methoxy-3-methyl-N-phenylbenzofuran-2-carboxamide (2a).
To a mixture of aniline (0.689g, 7.4mmol) in dichloromethane (25mL), 3-methyl-6-methoxybenzofuran-2-carboxylic acid (1a) (1.501g, 7.3mmol) was added with stirring. Then DMAP (0.094g, 0.77mmol) was added, followed by DCC (1.583g, 7.7mmol). The reaction was left to stir at room temperature for 23h. The reaction mixture was then filtered and the filtrate washed with water (20mL x 2), then 5% acetic acid (20mL x 2) and again with water (20mL x 2). The crude product was recrystallized from methanol to yield 2a as white crystals (1.37g, 67%), mp 176-178 °C. 
5,6-Dimethoxy-3-methyl-N-phenylbenzofuran-2-carboxamide (2b).
To a mixture of aniline (0.398g, 4.27mmol) in dichloromethane (15mL), 3-methyl-5,6-dimethoxybenzofuran-2-carboxylic acid (1b) (1.005g, 4.25mmol) was added with stirring. Then DMAP (0.090g, 0.44mmol) was added, followed by DCC (0.934g, 4.53mmol). The reaction was left to stir at room temperature for 23h. The reaction mixture was then filtered and the filtrate washed with water (20mL x 2), then 5% acetic acid (20mL x 2) and again with water (20mL x 2). The crude product was recrystallized from methanol to yield 2b as white crystals (0.94g, 71%), mp 
3-Methyl-N-phenylbenzofuran-2-carboxamide (2c).
To a mixture of aniline (0.690g, 7.41mmol) in dichloromethane (25mL), 3-methylbenzofuran-2-carboxylic acid (1c) (1.00g, 5.7mmol) was added with stirring. Then DMAP (0.116g, 0.57mmol) was added, followed by DCC (1.220g, 5.9mmol). The reaction was left to stir at room temperature for 23h. The reaction mixture was then filtered and the filtrate washed with water (20mL x 2), then 5% acetic acid (20mL x 2) and again with water (20mL x 2). The crude product was recrystallized from methanol to yield 2c as off-white crystals (0.896g, 63%), mp 118-120 °C. 
3-Methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide (KSCM-5).
Compound 2c ( -3-methyl-N-phenyl-N-(3-(piperidin-1-yl) Assays were performed using transiently or stably transfected cell lines (e.g., HEK293, COS, CHO, NIH3T3). Refer to Table 5 for radioligands and reference compounds listing. Data represent mean % inhibition (N = 4 determinations) for compound tested at receptor subtypes. Significant inhibition is considered > 50%. In cases where negative inhibition (-) is seen, this represents a stimulation of binding. Occasionally, compounds at high concentrations will non-specifically increase binding. The default concentration for primary binding experiments is 10uM.
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